TOPOI/PARP-1-IN-1, identified by the CAS number 2948352-16-5, is a chemical compound that functions primarily as an inhibitor of the enzymes topoisomerase I and poly(ADP-ribose) polymerase 1 (PARP-1). These enzymes play crucial roles in DNA replication and repair, making this compound of interest in cancer research and therapeutic development. The inhibition of PARP-1 is particularly significant in the context of cancer treatment, as it can enhance the efficacy of certain chemotherapeutic agents by preventing cancer cells from repairing DNA damage. The compound is characterized by its specific binding affinity to the target enzymes, which can lead to the induction of apoptosis in cancer cells. Additionally, TOPOI/PARP-1-IN-1 may exhibit properties such as solubility in organic solvents and stability under physiological conditions, although specific solubility and stability data would depend on the formulation and conditions. Overall, this compound represents a promising avenue for targeted cancer therapies, particularly in tumors with deficiencies in DNA repair mechanisms.

TOPOI/PARP-1-IN-1

2948352-16-5: TOPOI/PARP-1-IN-1, identified by the CAS number 2948352-16-5, is a chemical compound that functions primarily as an inhibitor of the enzymes topoisomerase I and poly(ADP-ribose) polymerase 1 (PARP-1). These enzymes play crucial roles in DNA replication and repair, making this compound of interest in cancer research and therapeutic development. The inhibition of PARP-1 is particularly significant in the context of cancer treatment, as it can enhance the efficacy of certain chemotherapeutic agents by preventing cancer cells from repairing DNA damage. The compound is characterized by its specific binding affinity to the target enzymes, which can lead to the induction of apoptosis in cancer cells. Additionally, TOPOI/PARP-1-IN-1 may exhibit properties such as solubility in organic solvents and stability under physiological conditions, although specific solubility and stability data would depend on the formulation and conditions. Overall, this compound represents a promising avenue for targeted cancer therapies, particularly in tumors with deficiencies in DNA repair mechanisms.

<p>Compound B6, also known as TOPOI/PARP-1-IN-1, is a dual inhibitor targeting TOPOI and PARP, exhibiting low cytotoxicity and oral activity with a PARP1 IC 50 of 0.09 μM. This compound effectively inhibits cancer cell proliferation and migration, induces cell cycle arrest at the G0/G1 phase, and triggers apoptosis. In murine models, TOPOI/PARP-1-IN-1 demonstrated a tumor growth inhibition rate (TGI) of 75.4% [1].</p>

CAS 2948352-16-5

TOPOI/PARP-1-IN-1

TOPOI/PARP-1-IN-1

Ref: TM-T87550